Based on their mean age at study inclusion (53 years) and the knowledge about the penetrance of the LRRK2 gene (28% at age 59 years [9]), approximately one out of four of their study participants with a LRRK2 mutation will develop clinical PD within the following six years. The gene discussed is LRRK2; the disease is Parkinson disease.